These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

362 related articles for article (PubMed ID: 34428592)

  • 1. Sleep Outcomes From AWAKE-HF: A Randomized Clinical Trial of Sacubitril/Valsartan vs Enalapril in Patients With Heart Failure and Reduced Ejection Fraction.
    Owens RL; Birkeland K; Heywood JT; Steinhubl SR; Dorn J; Grant D; Fombu E; Khandwalla R
    J Card Fail; 2021 Dec; 27(12):1466-1471. PubMed ID: 34428592
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The AWAKE-HF Study: Sacubitril/Valsartan Impact on Daily Physical Activity and Sleep in Heart Failure.
    Khandwalla RM; Grant D; Birkeland K; Heywood JT; Fombu E; Owens RL; Steinhubl SR;
    Am J Cardiovasc Drugs; 2021 Mar; 21(2):241-254. PubMed ID: 32978755
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Angiotensin-Neprilysin Inhibition in Acute Decompensated Heart Failure.
    Velazquez EJ; Morrow DA; DeVore AD; Duffy CI; Ambrosy AP; McCague K; Rocha R; Braunwald E;
    N Engl J Med; 2019 Feb; 380(6):539-548. PubMed ID: 30415601
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A randomized clinical trial on the short-term effects of 12-week sacubitril/valsartan vs. enalapril on peak oxygen consumption in patients with heart failure with reduced ejection fraction: results from the ACTIVITY-HF study.
    Halle M; Schöbel C; Winzer EB; Bernhardt P; Mueller S; Sieder C; Lecker LSM
    Eur J Heart Fail; 2021 Dec; 23(12):2073-2082. PubMed ID: 34591356
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Initiation of Angiotensin-Neprilysin Inhibition After Acute Decompensated Heart Failure: Secondary Analysis of the Open-label Extension of the PIONEER-HF Trial.
    DeVore AD; Braunwald E; Morrow DA; Duffy CI; Ambrosy AP; Chakraborty H; McCague K; Rocha R; Velazquez EJ;
    JAMA Cardiol; 2020 Feb; 5(2):202-207. PubMed ID: 31825471
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Influence of Ejection Fraction on Outcomes and Efficacy of Sacubitril/Valsartan (LCZ696) in Heart Failure with Reduced Ejection Fraction: The Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure (PARADIGM-HF) Trial.
    Solomon SD; Claggett B; Desai AS; Packer M; Zile M; Swedberg K; Rouleau JL; Shi VC; Starling RC; Kozan Ö; Dukat A; Lefkowitz MP; McMurray JJ
    Circ Heart Fail; 2016 Mar; 9(3):e002744. PubMed ID: 26915374
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of sacubitril/valsartan compared with enalapril in patients with chronic heart failure and reduced ejection fraction: Results from PARADIGM-HF India sub-study.
    Jain AR; Aggarwal RK; Rao NS; Billa G; Kumar S
    Indian Heart J; 2020; 72(6):535-540. PubMed ID: 33357641
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Activity Sensors to Evaluate the Effect of Sacubitril/Valsartan on Quality-of-Life in Heart Failure: rational and design of the AWAKE-HF study.
    Khandwalla RM; Birkeland K; Heywood JT; Steinhubl S; McCague K; Fombu E; Grant D; Riebman JB; Owens RL
    ESC Heart Fail; 2019 Dec; 6(6):1313-1321. PubMed ID: 31638338
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of Sacubitril/Valsartan on Physical and Social Activity Limitations in Patients With Heart Failure: A Secondary Analysis of the PARADIGM-HF Trial.
    Chandra A; Lewis EF; Claggett BL; Desai AS; Packer M; Zile MR; Swedberg K; Rouleau JL; Shi VC; Lefkowitz MP; Katova T; McMurray JJV; Solomon SD
    JAMA Cardiol; 2018 Jun; 3(6):498-505. PubMed ID: 29617523
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reduced Risk of Hyperkalemia During Treatment of Heart Failure With Mineralocorticoid Receptor Antagonists by Use of Sacubitril/Valsartan Compared With Enalapril: A Secondary Analysis of the PARADIGM-HF Trial.
    Desai AS; Vardeny O; Claggett B; McMurray JJ; Packer M; Swedberg K; Rouleau JL; Zile MR; Lefkowitz M; Shi V; Solomon SD
    JAMA Cardiol; 2017 Jan; 2(1):79-85. PubMed ID: 27842179
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness Analysis of Sacubitril/Valsartan vs Enalapril in Patients With Heart Failure and Reduced Ejection Fraction.
    Gaziano TA; Fonarow GC; Claggett B; Chan WW; Deschaseaux-Voinet C; Turner SJ; Rouleau JL; Zile MR; McMurray JJ; Solomon SD
    JAMA Cardiol; 2016 Sep; 1(6):666-72. PubMed ID: 27438344
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hemodynamic Effects of Sacubitril-Valsartan Versus Enalapril in Patients With Heart Failure in the EVALUATE-HF Study: Effect Modification by Left Ventricular Ejection Fraction and Sex.
    Mitchell GF; Solomon SD; Shah AM; Claggett BL; Fang JC; Izzo J; Abbas CA; Desai AS;
    Circ Heart Fail; 2021 Mar; 14(3):e007891. PubMed ID: 33663237
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cardiovascular biomarkers in patients with acute decompensated heart failure randomized to sacubitril-valsartan or enalapril in the PIONEER-HF trial.
    Morrow DA; Velazquez EJ; DeVore AD; Prescott MF; Duffy CI; Gurmu Y; McCague K; Rocha R; Braunwald E
    Eur Heart J; 2019 Oct; 40(40):3345-3352. PubMed ID: 31093657
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rationale and study design of OUTSTEP-HF: a randomised controlled study to assess the effect of sacubitril/valsartan and enalapril on physical activity measured by accelerometry in patients with heart failure with reduced ejection fraction.
    Edelmann F; Jaarsma T; Comin-Colet J; Schorr J; Ecochard L; Hussain RI; Piepoli MF
    Eur J Heart Fail; 2020 Sep; 22(9):1724-1733. PubMed ID: 32468672
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rationale and design of the comParIson Of sacubitril/valsartaN versus Enalapril on Effect on nt-pRo-bnp in patients stabilized from an acute Heart Failure episode (PIONEER-HF) trial.
    Velazquez EJ; Morrow DA; DeVore AD; Ambrosy AP; Duffy CI; McCague K; Hernandez AF; Rocha RA; Braunwald E
    Am Heart J; 2018 Apr; 198():145-151. PubMed ID: 29653636
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of Sacubitril/Valsartan vs Standard Medical Therapies on Plasma NT-proBNP Concentration and Submaximal Exercise Capacity in Patients With Heart Failure and Preserved Ejection Fraction: The PARALLAX Randomized Clinical Trial.
    Pieske B; Wachter R; Shah SJ; Baldridge A; Szeczoedy P; Ibram G; Shi V; Zhao Z; Cowie MR;
    JAMA; 2021 Nov; 326(19):1919-1929. PubMed ID: 34783839
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Early B-Type Natriuretic Peptide Change in HFrEF Patients Treated With Sacubitril/Valsartan: A Pooled Analysis of EVALUATE-HF and PROVE-HF.
    Myhre PL; Prescott MF; Murphy SP; Fang JC; Mitchell GF; Ward JH; Claggett B; Desai AS; Solomon SD; Januzzi JL
    JACC Heart Fail; 2022 Feb; 10(2):119-128. PubMed ID: 35115085
    [TBL] [Abstract][Full Text] [Related]  

  • 18. OUTSTEP-HF: randomised controlled trial comparing short-term effects of sacubitril/valsartan versus enalapril on daily physical activity in patients with chronic heart failure with reduced ejection fraction.
    Piepoli MF; Hussain RI; Comin-Colet J; Dosantos R; Ferber P; Jaarsma T; Edelmann F
    Eur J Heart Fail; 2021 Jan; 23(1):127-135. PubMed ID: 33314487
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sacubitril/Valsartan in Patients Hospitalized With Decompensated Heart Failure.
    Morrow DA; Velazquez EJ; Desai AS; DeVore AD; Lepage S; Park JG; Sharma K; Solomon SD; Starling RC; Ward JH; Williamson KM; Zieroth S; Hernandez AF; Mentz RJ; Braunwald E
    J Am Coll Cardiol; 2024 Mar; 83(12):1123-1132. PubMed ID: 38508844
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-Effectiveness of Sacubitril-Valsartan Combination Therapy Compared With Enalapril for the Treatment of Heart Failure With Reduced Ejection Fraction.
    King JB; Shah RU; Bress AP; Nelson RE; Bellows BK
    JACC Heart Fail; 2016 May; 4(5):392-402. PubMed ID: 27039128
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.